Oracle shares weekly forecast: Rebound odds stay low after nearly 5% slide on balance sheet strain

Oracle shares weekly forecast: Rebound odds stay low after nearly 5% slide on balance sheet strain
Oracle drops 4.90% this week

Shares of Oracle Corporation (ORCL) are trading near $119 after dropping close to 5% this week, as rebound odds remain low. Corporate activity and balance sheet strain linger over the stock, setting the tone for a cautious outlook heading into the new week.

ORCL price prediction
24H 2.53%
$119.25
48H 1.73%
$118.32
7D 1.14%
$117.64
1M -3.84%
$111.84
3M -27.07%
$84.82
6M -45.87%
$62.96
12M -48.58%
$59.81
Current price: $116.31 -2.7800 2.33%
Real-time Data 10:19
Daily range 118.25 Arrow from to Icon 123.14
Weekly range 118.25 Arrow from to Icon 130.76
Loading...

Highlights

  • Shares of Oracle have dropped 4.9% in the past week to $119.25, trading below all key daily moving averages.
  • Technical signals remain negative with downside momentum and consolidation expected below resistance at $126.06.
  • The projected trading range for the week ahead is $112.46 to $126.03, with support at $115.59 and strong downside risk.

Leverage jumps as aggressive debt and equity sale fuels AI expansion

Oracle completed a $10 billion senior notes offering alongside a $10 billion common stock sale at $116 per share to fuel its AI data center expansion, according to Yahoo Finance. This aggressive funding move has resulted in higher leverage and negative free cash flow, contributing to recent underperformance. Oracle also announced new federal contracts by adding the Department of Veterans Affairs and Department of War to its Health Information Network.

Oracle Corporation asset chart
Oracle Corporation price dynamics. Source: TradingView.

Bearish momentum persists as downside risk dominates despite neutral oscillators

The daily chart reveals a decisive downside move with volatility at 13.12%, but without a sustained trend, reflecting a sharp move lower without a sustained trend. Momentum signals remain negative, as seen in the MACD reading of -4.57 (Strong Sell), while oscillator readings from the RSI and CCI are neutral. Immediate support stands at $115.59, with resistance at $126.06 from the MA-20 and additional resistance from the Ichimoku Kijun at $128.87. Overall, indicators point to further risk on the downside, while range-bound action persists.

Downside bias prevails in the coming week amid resistance at $126.06

In the week ahead, Oracle is expected to trade between $112.46 and $126.03, with a very high probability of a decrease (more than 80%) and a very low probability of an increase (less than 20%). The base case sees continued consolidation below resistance at $126.06. Upside attempts above $126.06 would challenge $128.87, but the risk remains tilted downward. A break below support at $115.59 would open the door for further declines toward the lower end of the expected range.

Sholanke Dele, market strategist, believes Oracle shares have entered a risk-heavy phase after this week’s sharp 5% drop to $119. He sees corporate funding actions — notably the $10 billion notes and $10 billion equity sale — amplifying leverage risks and weighing on sentiment, despite new federal contracts in the health segment. The daily technicals confirm a negative bias, with support at $115.59 and resistance at $126.06 keeping the stock in a vulnerable, range-bound setup. In his view, downward risk will persist unless the shares reclaim resistance, with a high probability of further declines if support gives way. "Until Oracle breaks above $126.06, I remain defensively positioned — balance sheet pressure and negative momentum outweigh any short-term recovery hopes."

Earlier, analysts noted that Oracle shares remained under pressure despite ongoing federal health network expansion and AI-focused initiatives, with technicals favoring a cautious near-term stance. The latest developments reinforce expectations for continued weakness, with traders advised to monitor the $115.59 support level for signs of further downside risk.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.